Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Convergence

Biogen Idec building

Patient death probably not linked to Biogen Idec’s Tecfidera

Stock recovers after unfounded claims

Biogen Idec building

Biogen Idec’s long-acting beta interferon moves ahead in MS

US and EU accept filings for long-acting multiple sclerosis drug Plegridy

Biogen Idec building

Biogen Idec signs brain research deal with Edinburgh University

Will identify potential treatments for multiple sclerosis and motor neurone disease

Biogen Idec building

Biogen Idec says Tecfidera launch delayed in Europe

Company wants to resolve patent and regulatory data protection issues for oral MS drug

- PMLiVE

Biogen Idec appoints Harvard professor as CSO

First major industry role for Spyros Artavanis-Tsakonas after rich academic career

Biogen Idec building

FDA starts review of Biogen Idec’s haemophilia A therapy

Could gain US approval by the first quarter of 2014

Biogen Idec building

Biogen Idec’s Tecfidera approved in US

Green light from FDA closely follows MS drug's European approval

- PMLiVE

CHMP backs oral MS drugs from Sanofi, Biogen Idec

Tecfidera and Aubagio recommended for use in Europe

Biogen Idec building

Biogen wins extra patent protection for MS drug Tecfidera

Dosing patent provides exclusivity until 2028

- PMLiVE

Royalty Pharma mulls bid for Elan

Follows Biogen’s $3.25bn acquisition of Tysabri from Elan

- PMLiVE

Merck to develop biosimilars with Samsung-Biogen joint venture

Agreement with Samsung Bioepis covers several candidates

- PMLiVE

Biogen gains full rights to Tysabri in $3.25bn deal with Elan

Ends decade-long partnership for MS drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links